NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

ImmunoGen Inc (F: IMU)

 
IMU Technical Analysis
5
As on 13th Feb 2024 IMU STOCK Price closed @ 0.10 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 7.66 & Strong Sell for SHORT-TERM with Stoploss of 5.44 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

IMUSTOCK Price

Open 0.11 Change Price %
High 0.12 1 Day -28.64 -99.65
Low 0.10 1 Week -26.71 -99.63
Close 0.10 1 Month -26.61 -99.63
Volume 27090799 1 Year -5.18 -98.11
52 Week High 28.95 | 52 Week Low 0.10
 
F Germany Most Active Stocks
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
 
F Germany Top Gainers Stocks
JYR 1000000.00 10000000000.00%
JYR 1000000.00 10000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
0AI 11.30 14025.00%
0AI 11.30 14025.00%
SUE1 12.60 12500.00%
HGF2 7.40 1380.00%
 
F Germany Top Losers Stocks
T27 0.00 -100.00%
HA3 0.00 -100.00%
HA3 0.00 -100.00%
HA3 0.00 -100.00%
15B 0.00 -100.00%
15B 0.00 -100.00%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
IMU 0.10 -99.65%
 
 
IMU
Daily Charts
IMU
Intraday Charts
Whats New @
Bazaartrend
IMU
Free Analysis
 
IMU Important Levels Intraday
RESISTANCE0.14
RESISTANCE0.13
RESISTANCE0.12
RESISTANCE0.11
SUPPORT0.09
SUPPORT0.08
SUPPORT0.07
SUPPORT0.06
 
IMU Forecast November 2024
4th UP Forecast3.11
3rd UP Forecast2.14
2nd UP Forecast1.55
1st UP Forecast0.95
1st DOWN Forecast-0.75
2nd DOWN Forecast-1.35
3rd DOWN Forecast-1.94
4th DOWN Forecast-2.91
 
IMU Weekly Forecast
4th UP Forecast0.76
3rd UP Forecast0.55
2nd UP Forecast0.42
1st UP Forecast0.29
1st DOWN Forecast-0.09
2nd DOWN Forecast-0.22
3rd DOWN Forecast-0.35
4th DOWN Forecast-0.56
 
IMU Forecast2024
4th UP Forecast55.79
3rd UP Forecast37.93
2nd UP Forecast26.89
1st UP Forecast15.85
1st DOWN Forecast-15.65
2nd DOWN Forecast-26.69
3rd DOWN Forecast-37.73
4th DOWN Forecast-55.59
 
 
IMU Other Details
Segment EQ
Market Capital 1006230784.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
IMU Address
IMU
 
IMU Latest News
 
Your Comments and Response on ImmunoGen Inc
 
IMU Business Profile
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. Address: 830 Winter Street, Waltham, MA, United States, 02451-1477
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service